Biomimetic nanoparticle technology for cardiovascular disease detection and treatment

Park, Joon Ho; Dehaini, Diana; Zhou, Jiarong; Holay, Maya; Fang, Ronnie H.; Zhang, Liangfang

doi:10.1039/c9nh00291j

Cited by 94 publications

(47 citation statements)

References 226 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhang et al recently reported neutrophil membrane-coated nanoparticles to alleviate inflammatory arthritis and platelet membrane-coated metal-organic framework nanoparticles to target gene silencing in vivo 22 , 23 . Most recently, cell membrane coating nanotechnology has been applied to treat certain cardiovascular diseases 24 . For instance, it has been reported that platelet membrane-coated NPs have been applied to detect and treat atherosclerosis 25 , 26 .…”

Section: Introductionmentioning

confidence: 99%

Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications

et al. 2021

View full text Add to dashboard Cite

Atherosclerosis (AS), the underlying cause of most cardiovascular events, is one of the most common causes of human morbidity and mortality worldwide due to the lack of an efficient strategy for targeted therapy. In this work, we aimed to develop an ideal biomimetic nanoparticle for targeted AS therapy. Methods: Based on macrophage “homing” into atherosclerotic lesions and cell membrane coating nanotechnology, biomimetic nanoparticles (MM/RAPNPs) were fabricated with a macrophage membrane (MM) coating on the surface of rapamycin-loaded poly (lactic-co-glycolic acid) copolymer (PLGA) nanoparticles (RAPNPs). Subsequently, the physical properties of the MM/RAPNPs were characterized. The biocompatibility and biological functions of MM/RAPNPs were determined in vitro . Finally, in AS mouse models, the targeting characteristics, therapeutic efficacy and safety of the MM/RAPNPs were examined. Results: The advanced MM/RAPNPs demonstrated good biocompatibility. Due to the MM coating, the nanoparticles effectively inhibited the phagocytosis by macrophages and targeted activated endothelial cells in vitro . In addition, MM-coated nanoparticles effectively targeted and accumulated in atherosclerotic lesions in vivo . After a 4-week treatment program, MM/RAPNPs were shown to significantly delay the progression of AS. Furthermore, MM/RAPNPs displayed favorable safety performance after long-term administration. Conclusion: These results demonstrate that MM/RAPNPs could efficiently and safely inhibit the progression of AS. These biomimetic nanoparticles may be potential drug delivery systems for safe and effective anti-AS applications.

show abstract

Section: Introductionmentioning

confidence: 99%

Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The microencapsulation technique represents another potential strategy for a successful administration of IL-4/IL-13 [ 187 ]. A recent study demonstrated that IL-4/IL-13-encapsulated biodegradable microspheres displayed prolonged half-life and effectively suppressed inflammatory activity of osteoarthritic chondrocytes in in vitro assay [ 188 ].…”

Section: Therapeutic Perspectivesmentioning

confidence: 99%

Significance of Interleukin (IL)-4 and IL-13 in Inflammatory Arthritis

Iwaszko

Biały

Bogunia‐Kubik

2021

Cells

155

View full text Add to dashboard Cite

Interleukin (IL)-4 and IL-13 belong to the T helper 2 (Th2) cytokine family, along with IL-3, IL-5, and IL-9. These cytokines are key mediators of allergic inflammation. They have important immunomodulatory activities and exert influence on a wide variety of immune cells, such as B cells, eosinophils, basophils, monocytes, fibroblasts, endothelial cells, airway epithelial cells, smooth muscle cells, and keratinocytes. Recent studies have implicated IL-4 and IL-13 in the development of various autoimmune diseases. Additionally, these cytokines have emerged as potential players in pathogenesis of inflammatory arthritis. Recent findings suggest that the IL-4 and IL-13 might play a significant role in the downregulation of inflammatory processes underlying RA pathology, and beneficially modulate the course of the disease. This review summarizes the biological features of the IL-4 and IL-13 and provides current knowledge regarding the role of these cytokines in inflammatory arthritis.

show abstract

“…However, triggers of atherosclerosis, which include hypertension, a diet high in saturated fats and obesity, initiate the expression of adhesion molecules that allow the entry of lipids into the vascular wall and the subsequent recruitment of leukocytes to the affected area (Rafieian-Kopaei et al, 2014). The use of cell membrane-based biomimetic NPs for these applications have focused on mimicking various cell membranes (e.g., as platelets and leukocytes) and protein complexes important for good cardiovascular health [i.e., high-density lipoprotein (HDL); Park et al, 2020].…”

Section: Cardiovascular Diseasementioning

confidence: 99%

Cell Membrane-Based Biomimetic Nanoparticles and the Immune System: Immunomodulatory Interactions to Therapeutic Applications

Sushnitha

Evangelopoulos

Tasciotti

et al. 2020

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Nanoparticle-based drug delivery systems have been synthesized from a wide array of materials. The therapeutic success of these platforms hinges upon their ability to favorably interact with the biological environment (both systemically and locally) and recognize the diseased target tissue. The immune system, composed of a highly coordinated organization of cells trained to recognize foreign bodies, represents a key mediator of these interactions. Although components of this system may act as a barrier to nanoparticle (NP) delivery, the immune system can also be exploited to target and trigger signaling cues that facilitate the therapeutic response stemming from systemic administration of NPs. The nano-bio interface represents the key facilitator of this communication exchange, where the surface properties of NPs govern their in vivo fate. Cell membrane-based biomimetic nanoparticles have emerged as one approach to achieve targeted drug delivery by actively engaging and communicating with the biological milieu. In this review, we will highlight the relationship between these biomimetic nanoparticles and the immune system, emphasizing the role of tuning the nano-bio interface in the immunomodulation of diseases. We will also discuss the therapeutic applications of this approach with biomimetic nanoparticles, focusing on specific diseases ranging from cancer to infectious diseases. Lastly, we will provide a critical evaluation on the current state of this field of cell membrane-based biomimetic nanoparticles and its future directions in immune-based therapy.

show abstract

Biomimetic nanoparticle technology for cardiovascular disease detection and treatment

Abstract: Biomimetic nanoparticle technology has the potential to significantly improve the clinical management of cardiovascular disease.

Cited by 94 publications

References 226 publications

Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications

Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications

Significance of Interleukin (IL)-4 and IL-13 in Inflammatory Arthritis

Cell Membrane-Based Biomimetic Nanoparticles and the Immune System: Immunomodulatory Interactions to Therapeutic Applications

Contact Info

Product

Resources

About